Lenvatinib and pembrolizumab in advanced gastric cancer
Mené au Japon sur 29 patients atteints d’un cancer de l’estomac de stade avancé, cet essai de phase II évalue l’efficacité, du point de vue du taux de réponse objective, et la toxicité du lenvatinib en combinaison avec le pembrolizumab en traitement de première ou deuxième ligne (durée médiane de suivi : 12,6 mois)
Résumé en anglais
Despite its declining incidence, gastric cancer still represents a substantial global health burden, being the third leading cause of cancer death worldwide. Most patients present with advanced disease at diagnosis. In the past 20 years, the only achievements in the treatment of advanced gastric cancer have been the use of trastuzumab plus chemotherapy as a first-line treatment and ramucirumab plus paclitaxel in the second-line setting. Although immunotherapy could have a role in gastric cancer, the results achieved so far have been controversial, and a clear benefit has only been shown in microsatellite instable or Epstein-Barr virus-positive tumours. Therefore, new effective systemic treatments for advanced gastric cancer are eagerly awaited.
